Celldex Therapeutics (CLDX) Share-based Compensation (2010 - 2026)

Celldex Therapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• On a quarterly basis, Share-based Compensation fell 8.51% year-over-year to $8.5 million in Q1 2026; TTM through Mar 2026 was $35.9 million, a 1.15% decrease from a year earlier, with the FY2025 full-year figure at $65.3 million, down 15.3% from the prior year.
• Share-based Compensation retreated to $8.5 million in Q1 2026 per CLDX's latest filing, from $8.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $72.8 million in Q3 2025 and bottomed at $3.2 million in Q1 2022.
• The 5-year median for Share-based Compensation is $7.2 million (2023), against an average of $10.7 million.
• Biggest YoY gain for Share-based Compensation was 656.76% in 2025; the steepest drop was 8.91% in 2025.
• Year by year, Share-based Compensation stood at $4.5 million in 2022, then soared by 59.98% to $7.2 million in 2023, then soared by 35.61% to $9.8 million in 2024, then decreased by 8.91% to $8.9 million in 2025, then slipped by 4.33% to $8.5 million in 2026.
• Per Business Quant, the three latest CLDX Share-based Compensation figures stand at $8.5 million (Q1 2026), $8.9 million (Q4 2025), and $72.8 million (Q3 2025).